Skip to content
10-Q/A

Quarterly Report

Biostax Corp.

0001493152-24-033014

← back to feed
Filed
Aug 19, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 20, 2024 83.71M sh
Shares Diluted restated Q1 2024 · Mar 31, 2024 83.71M sh
Shares Diluted Q1 2024 · Mar 31, 2023 83.24M sh
Operating Cash Flow restated Q1 2024 · Mar 31, 2024 −$33.31K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$265.5K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $2.1K
Cash And Equivalents Q1 2024 · Dec 31, 2023 $29.79K
Stockholders Equity restated Q1 2024 · Mar 31, 2024 −$4.87M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$4.53M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$2.78M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$2.51M
Current Liabilities restated Q1 2024 · Mar 31, 2024 $4.88M
Current Liabilities restated Q1 2024 · Dec 31, 2023 $4.56M
Total Liabilities restated Q1 2024 · Mar 31, 2024 $4.88M
Total Liabilities restated Q1 2024 · Dec 31, 2023 $4.56M
Current Assets Q1 2024 · Mar 31, 2024 $2.1K
Current Assets Q1 2024 · Dec 31, 2023 $29.79K
Total Assets Q1 2024 · Mar 31, 2024 $7.6K
Total Assets Q1 2024 · Dec 31, 2023 $35.29K
Eps Diluted Q1 2024 · Mar 31, 2024 $0.00
Eps Diluted Q1 2024 · Mar 31, 2023 $0.00
Eps Basic Q1 2024 · Mar 31, 2024 $0.00
Eps Basic Q1 2024 · Mar 31, 2023 $0.00
Sga Expense restated Q1 2024 · Mar 31, 2024 $254.25K
Sga Expense Q1 2024 · Mar 31, 2023 $207.52K
Rd Expense Q1 2024 · Mar 31, 2024 $11.08K
Rd Expense Q1 2024 · Mar 31, 2023 $180.92K
Net Income restated Q1 2024 · Mar 31, 2024 −$352.64K
Net Income Q1 2024 · Mar 31, 2023 −$416.12K
Operating Income restated Q1 2024 · Mar 31, 2024 −$265.33K
Operating Income Q1 2024 · Mar 31, 2023 −$401.82K